Skip to content
Companies

Tempest Therapeutics

In vivo CAR-T therapies for autoimmune disease and cancer

Raised to date

$13.6M

of $13.6M offered across 3 Form D filings

Investors
3
Last filed
Oct 13, 2026

About

Tempest Therapeutics is a clinical-stage biotechnology company in Brisbane, California, developing in vivo CAR-T cell therapies for autoimmune disease and cancer. Following an all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience that closed in early 2026, the company unveiled a next-generation in vivo CAR-T pipeline in July 2026. Its approach pairs a CD7-targeted mRNA lipid nanoparticle delivery platform with a dual-targeting CAR architecture, engineering CAR-T cells inside the patient rather than through ex vivo manufacturing. Tempest also retains earlier small-molecule oncology programs, TPST-1120 and TPST-1495.

Combines a CD7-targeted lipid nanoparticle delivery system with a dual-target CD19/BCMA CAR architecture to generate CAR-T cells in vivo, removing the cell-manufacturing step that makes conventional CAR-T slow and costly, and targeting both CD4+ and CD8+ T-cell populations.

Funding

$7.5M round, first sold Sep 2026$7.5M soldMar 2026JunSep
Now
  • Security to be acquiredFiled Oct 13, 2026Form D
    $7.5M/ $7.5M
  • EquityFiled Jun 23, 2026Form D
    $4.1M/ $4.1M
  • EquityFiled Apr 3, 2026Form D
    $2M/ $2M

Product

TPST-4003

Clinical-stage cell therapy candidate

The lead in vivo CAR-T candidate, pairing Tempest's CD7-targeted mRNA lipid nanoparticle (CD7-tLNP) delivery platform with a dual-targeting CD19/BCMA chimeric antigen receptor.

  • CD7-targeted mRNA lipid nanoparticle delivery
  • Dual CD19/BCMA CAR targeting
  • Engineered for both CD4+ and CD8+ T-cell populations

Built for

Patients with autoimmune diseases such as myasthenia gravis and multiple sclerosis, and patients with hematologic malignancies and solid tumors, reached through clinical investigators, treating physicians, and pharmaceutical partners

People on file